国: 南アフリカ
言語: 英語
ソース: South African Health Products Regulatory Authority (SAHPRA)
Hexal
DANTRON™ 4 mg or 8 mg film-coated tablets SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): DANTRON™ 4 mg or 8 mg film-coated tablets COMPOSITION DANTRON 4 mg film-coated tablets: Each film-coated tablet contains ondansetron 4 mg (as hydrochloride dihydrate). DANTRON 8 mg film-coated tablets: Each film-coated contains ondansetron 8 mg (as hydrochloride dihydrate). PHARMACOLOGICAL CLASSIFICATION A 5.10 Medicines affecting autonomic functions. Serotonin antagonists. PHARMACOLOGICAL ACTION Ondansetron is a potent, highly selective 5-HT 3 receptor-antagonist. Ondansetron’s actual mechanism of action in the control of nausea and vomiting is unknown. Chemotherapeutic agents and radiotherapy may cause release of 5-HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5-HT 3 receptors. The initiation of this reflex is blocked by ondansetron. Activation of vagal afferents may also cause a release of 5-HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is due to the antagonism of 5-HT 3 receptors on neurons located both in the peripheral and central nervous system. In psychomotor testing, ondansetron does not cause sedation nor impair performance. Pharmacokinetics: Plasma prolactin concentrations are not altered by ondansetron. Ondansetron is rapidly absorbed following oral administration, with maximum plasma concentrations of about 30 ng/mL being attained approximately 1,6 hours after an 8 mg dose. The absolute oral bioavailability of the drug is approximately 60%. The disposition of ondansetron following both intravenous and ora 完全なドキュメントを読む